



# Vitamin D and biomarkers of sex steroid hormones are non-linearly and inversely related to all-cause mortality: results from NHANES III

Hind A. Beydoun<sup>1\*</sup>, Shaker M. Eid<sup>2</sup>, Hueiwang Anna Jeng<sup>3</sup>, Alan B. Zonderman<sup>4</sup> and May A. Beydoun<sup>4</sup>

\*Correspondence: [hindb1972@gmail.com](mailto:hindb1972@gmail.com)



CrossMark

← Click for updates

<sup>1</sup>Graduate Program in Public Health, Eastern Virginia Medical School, Norfolk, VA, USA.

<sup>2</sup>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

<sup>3</sup>Department of Community and Environmental Health, Old Dominion University, Norfolk, VA, USA.

<sup>4</sup>Laboratory of Epidemiology and Population Sciences, National Institute on Aging Intramural Research Program, Baltimore, MD, USA.

## Abstract

**Background:** In men, hypovitaminosis D as well as high and low testosterone levels have been linked to adverse events, including death. A biological interaction has been previously suggested between vitamin D and androgens. In a cohort study using Third National Health and Nutrition Examination Survey data, we simultaneously investigated circulating vitamin D and biomarkers of sex steroid hormones as predictors of all-cause mortality.

**Methods:** Age-adjusted and fully-adjusted Cox regression models were constructed to estimate hazard ratios (HR) and their 95% confidence intervals (CI). Whereas the vitamin D sufficient group ( $25(\text{OH})\text{D}_3 \geq 30$  ng/ml) was selected as a referent, biomarkers of sex steroid hormones (testosterone, estradiol, SHBG) were defined as Loge-transformed continuous variables.

**Results:** Of 1,472 men with a mean age of 42.1 years at baseline, 382 died over a median of 192 months of follow-up. Estradiol levels were significantly higher among vitamin D deficient compared to vitamin D sufficient men and sex hormone binding globulin level was significantly higher in vitamin D sufficient compared to vitamin D insufficient or deficient groups. An inverse non-linear relationship was observed between all-cause mortality rate and levels of testosterone, estradiol and vitamin D, in fully-adjusted models. There were no significant interaction effects between vitamin D and sex steroid hormones in relation to all-cause mortality rate.

**Conclusions:** Vitamin D and sex steroid hormones, but not sex hormone binding globulin, may be inversely and non-linearly related to all-cause mortality among adult men, after adjustment for baseline demographic, socioeconomic, lifestyle and clinical characteristics.

**Keywords:** All-cause mortality, androgens; cohort study, estradiol, sex hormone binding globulin, testosterone, vitamin D

## Introduction

In men, hypovitaminosis D as well as both high or low testosterone levels have been linked to adverse events, including death. Vitamin D is a fat-soluble secosteroid hormone endowed with pleiotropic effects [1,2]. Besides the well-known function of vitamin D in promoting *in vitro* bone mineralization and prevention of osteoporosis and bone fracture through intestinal calcium absorption [3,4], mounting evidence has linked hypovitaminosis D to musculoskeletal diseases [5], cancer [6],

autoimmune diseases, type 2 diabetes, cardiovascular disease [6,7] and all-cause mortality [5]. The main source of vitamin D is cholecalciferol (vitamin D<sub>3</sub>), synthesized in the skin by ultraviolet radiation [2]; pro-vitamin D<sub>3</sub> (7-dehydrocholesterol) is converted to pre-vitamin D<sub>3</sub>, which isomerizes into cholecalciferol and is later converted to calcitriol ( $1,25(\text{OH})_2\text{D}_3$ ) through a two-step enzymatic pathway involving liver 25-hydroxylase (CYP2R1) and kidney 1- $\alpha$ -hydroxylase (CYP27B1) [2,8,9]. Vitamin D status is assessed by measuring  $25(\text{OH})\text{D}_3$  [8]. Currently, the

Institute of Medicine advises  $25(\text{OH})\text{D}_3 \geq 20$  ng/ml but Endocrine Society advises  $25(\text{OH})\text{D}_3 \geq 30$  ng/ml, partly due to lack of adequate assays for vitamin D<sub>3</sub> quantification; thus, individuals are considered sufficient if  $25(\text{OH})\text{D}_3 \geq 30$  ng/ml ( $\geq 74$  nmol/L), insufficient if  $25(\text{OH})\text{D}_3$  is 20-29 ng/ml (50-74 nmol/L), and deficient if  $25(\text{OH})\text{D}_3 < 20$  ng/ml ( $< 50$  nmol/L) [5,7]. A biological interaction has been previously suggested between vitamin D and androgens [5,10-12]. Specifically, androgens may increase 1- $\alpha$ -hydroxylase, a key enzyme in vitamin D metabolism, and regulation of gene expression by vitamin D metabolites is modified according to androgen levels [5]. Numerous biological mechanisms have been proposed in an effort to explain the joint protective effects of vitamin D and sex steroids on bone fracture which is generally less among males compared to females [12], while other studies have suggested a contribution for testicular vitamin D metabolism [11].

The key androgen, in men, is testosterone, 50-60% of which is bound with high affinity to sex hormone binding globulin (SHBG), and the remaining 40-50% is bound loosely to albumin and other proteins, leaving 1-3% as 'free' testosterone [13]. The clinical significance of testosterone level in men remains controversial [5,14,15], with low and high levels of testosterone linked to deleterious outcomes [16]. Starting in the 3<sup>rd</sup>-4<sup>th</sup> decade of life, male aging is accompanied by 0.4-2.6% annual decline in total testosterone and 0.2% annual decline in 'free' testosterone resulting from gradual rise in SHBG, implying a clinical significance for measuring 'free' testosterone [5,17,18]. Age-related decline in endogenous testosterone, or male hypogonadism, has been associated with reduced libido and vitality, depression, sarcopenia, obesity, dyslipidemia, hypertension, metabolic syndrome, type 2 diabetes, stroke, atherosclerosis, subclinical inflammation, osteoporosis, trauma fracture and mortality risk [13,16,19-21]; an increasing level of SHBG, which predominantly carries testosterone and estradiol in the blood, has also been associated with cardiovascular risk factors and higher risk for premature death [22]. Similarly, when administered at high doses, exogenous testosterone has been correlated with sudden cardiac death and liver disease [16,23,24]. However, perceived health benefits of low dose exogenous testosterone may have contributed to its widespread use without approved change in indication [16,22,25-27].

The purpose of this population-based cohort study is to simultaneously investigate vitamin D and biomarkers of sex steroid hormones (testosterone, estradiol, SHBG as predictors of all-cause mortality among adult men in the Third National Health and Nutrition Examination Survey (NHANES III).

## Methods

### Study population

The National Center for Health Statistics implemented NHANES III between 1988 and 1994 in two phases (Phase I: 1988-1991, Phase II: 1991-1994) using a complex multistage probability sample design [28]. This study utilized question-

naire, physical examination and laboratory data from Phase I of NHANES III. Public-use datasets, including *adult* (n=20,050), *exam* (n=31,311), *examdr* (n=30,818), *lab* (n=29,314), *lab2* (n=29,314), *nhanes3* (n=33,994) and *sshormon* (n=1,636) were merged to select male adults (18 years and older) with serum specimens analyzed for vitamin D, biomarkers of sex steroid hormones and all-cause mortality data. A total of 1,472 NHANES III participants were included in the study. NHANES III is compliant with ethical rules of human experimentation stated in the Declaration of Helsinki, including approval by institutional review board and informed consent.

## Measures

### All-cause mortality

Mortality linkage of NHANES III with the National Death Index provides the opportunity to investigate associations of a wide range of characteristics at baseline with mortality rates at follow-up through December 31, 2006. Variables provided in this linked mortality file include sequence number, eligibility status, assigned vital status, mortality source, person-months of follow-up from interview date, person-months of follow-up from Mobile Examination Center (MEC) or home examination date and underlying multiple causes of death [29]. In this analysis, an event was defined as death from any cause during the follow-up period, starting at date of MEC examination and ending before December 31, 2006. Sensitivity analyses were performed to examine shorter durations (5 years and 10 years) of follow-up, yielding similar results to the total follow-up period.

### Vitamin D

Serum  $25(\text{OH})\text{D}_3$  concentration was determined in ng/mL (range: 5-160.3 ng/mL; limit of detection is 3.5 ng/mL) and nmol/L (range: 12.5-400.1 nmol/L; limit of detection is 8.7 nmol/L) at the National Center for Environmental health using DiaSorin radioimmunoassay kit (Stillwater, MN) [30,31]. NHANES documentation did not include inter- or intra-assay coefficients of variation for vitamin D. Because of skewed distribution, vitamin D concentration was  $\log_e$ -transformed or defined as a categorical variable (Deficient:  $< 20$  ng/ml; Insufficient: 20- $< 30$  ng/ml; Sufficient:  $\geq 30$  ng/ml), taking the sufficient group as a referent.

### Biomarkers of sex steroids

Serum testosterone, estradiol and SHBG concentrations were quantitatively determined using immunoassay techniques. NHANES documentation did not include inter-assay and intra-assay coefficients of variation for sex steroid hormones. Because of skewed distributions,  $\log_e$ -transformation and categorization in quintiles were performed for biomarkers of sex steroid hormones.

### Testosterone

Elecsys Testosterone was used to measure circulating testos-

terone concentration and was based on a competitive test principle using a monoclonal antibody directed against testosterone. The measuring range for testosterone is 0.069-52.00 nmol/L or 0.020-15.00 ng/mL, with a lower detection limit of 0.069 nmol/L (0.02 ng/mL) and a functional sensitivity (level at which between-run coefficient of variation is less than or equal to 20%) of 0.42 nmol/L (0.12 ng/mL) [32].

### **Estradiol**

Elecsys Estradiol II was used to measure circulating estradiol concentration and employs a competitive test principle using a polyclonal antibody specifically directed against 17 $\beta$ -estradiol. The measuring range for estradiol is 18.4-15,781 pmol/L (5.00-4,300 pg/mL), with a lower detection limit of 18.4 pmol/L (5.0 pg/mL) and a functional sensitivity (level at which between-run coefficient of variation is less than or equal to 20%) of 44 pmol/L (12 pg/mL) [33].

### **Sex hormone binding globulin**

Elecsys SHBG is used to measure SHBG concentration and employs two monoclonal antibodies specifically directed against it. The measuring range for SHBG is 0.350-200 nmol/L, with a lower detection limit of 0.35 nmol/L [34].

### **Demographic, socioeconomic, lifestyle and clinical characteristics**

*Age* (continuous; '18-20', '20-39', '40-59', '60+' years), *education* ('Less than High School', 'High School', 'More than High School'), *race/ethnicity* ('Non-Hispanic White', 'Non-Hispanic Black', 'Hispanic', 'Other'), *area of residence* ('Metropolitan', 'Other'), *poverty income ratio* (continuous; '<100%', '100%-<200%', '≥200%'), *marital status* ('Married/Co-habiting', 'Not married'), *smoking status* ('Current smoker', 'Ex-smoker', 'Never smoker'), *alcohol consumption* (at least 12 glasses in the past 12 months) ('yes', 'no'), *body mass index* (BMI) based on directly measured weight and height (continuous; '<25', '25-<30', '30+' kg/m<sup>2</sup>), *waist-to-hip ratio* defined as ratio of directly measured waist and hip circumferences (continuous; '≤0.9', '>0.9'), *self-rated health* ('excellent', 'very good', 'good', 'fair', 'poor'), *history of chronic conditions* including arthritis, asthma, chronic bronchitis, emphysema, congestive heart failure, stroke, diabetes and cancer ('yes', 'no'), and *physical activity* (continuous; '0', '>0-<100 METS', '100-<200 METS', '200-<300 METS', '≥300 METS').

### **Statistical analysis**

Statistical analyses were performed using STATA version 12 (STATA Corporation, College Station, TX). Whereas frequencies and percentages were computed for categorical variables, for continuous variables mean, median, standard deviation (SD), standard errors of the mean (SEM) and inter-quartile ranges were computed, as appropriate. Shapiro-Wilk's normality test was applied and continuous exposure variables were log<sub>e</sub>-transformed, as needed. One-way ANOVA tests with post-hoc comparisons evaluated using Bonferroni corrections

were used for comparing log<sub>e</sub>-transformed testosterone, estradiol and sex hormone-binding globulin concentrations across vitamin D status groups. Kaplan-Meier curves were constructed and log-rank tests were used to examine bivariate relationships between exposure variables (defined in quintiles) and survival. For multivariable analyses, hazard ratios (HR) and their 95% confidence intervals (CI) were calculated using Cox regression models. Fully-adjusted models were controlled for age (continuous), race/ethnicity, smoking status, and physical activity (categorical). Furthermore, we examined non-linearity by including quadratic terms for exposure variables and evaluated the interaction between vitamin D status and biomarkers of sex steroid hormones in age-adjusted and fully-adjusted models. Several aspects of NHANES III design were taken into account in data analyses, including sampling weights and complex survey design (primary sampling unit (PSU) and strata). Three full-sample and four sub-sample weights are available in NHANES III. For this analysis, we applied the MECweights with strata and PSU based on Phases I of NHANES III (i.e., 3 years). Sampling weights were used to correctly estimate population prevalence rates, means and other statistics while accounting for differential probabilities of selection, non-coverage, non-response and over-sampling of sub-populations. Two-sided statistical tests were performed at alpha of 0.05.

### **Results**

**Table 1** describes baseline demographic, socioeconomic, lifestyle and clinical characteristics of study participants. Of 1,472 men with (mean±SEM) age of (42.1±0.6) years at baseline, 77% were non-Hispanic White, 70% were married or cohabiting, 47% had more than high school education and nearly 10% were below the PIR. Whereas 35% were never smokers and 71% drank alcohol in the past 12 months, 18% were obese, 71% exhibiting central obesity, 13% reported fair or poor self-rated health and 28% reported having major chronic conditions, and physical activity was, on average, 139.3±8.2 METS. Descriptive statistics for vitamin D and biomarkers of sex steroid hormones are also presented in **Table 1**.

Vitamin D was weakly correlated with biomarkers of sex steroid hormones including testosterone ( $r_{\text{spearman}}=0.08$ ), estradiol ( $r_{\text{spearman}}=-0.07$ ) and SHBG ( $r_{\text{spearman}}=0.09$ ). When log<sub>e</sub>-transformed testosterone, estradiol and SHBG, were compared among vitamin D sufficient, insufficient and deficient men, estradiol levels were significantly higher among vitamin D deficient compared to vitamin D sufficient men and sex hormone binding globulin level was significantly higher in vitamin D sufficient compared to vitamin D insufficient or deficient groups (**Table 2**).

A total of 382 men died over a median of 192 months with an interquartile range of 183 to 202 months of follow-up (<5 years:100; 5-<10 years:105; ≥10 years:1,267), for an estimated all-cause mortality rate of 16.7% (95%CI:14.8%-18.8%). Kaplan-Meier curves were constructed to examine all-cause

**Table 1. Demographic, socioeconomic, lifestyle and clinical characteristics in adult men in the study sample (n=1472)–Third National Health and Nutrition Examination Survey.**

Characteristic	Mean±SEM or %
<b>N</b>	1472
<b>Age (years):</b>	
Mean±SEM	42.1±0.6
<20	3.1
20-39	47.5
40-59	31.5
60+	17.9
<b>Race / Ethnicity:</b>	
Non-Hispanic White	77.4
Non-Hispanic Black	9.9
Mexican-American	5.1
Other	7.4
<b>Marital status:</b>	
Married / Cohabiting	69.6
Not Married	30.4
<b>Education:</b>	
Less than High School	23.6
High School	29.2
More than High School	47.2
<b>Poverty-Income Ratio:</b>	
Mean±SEM	3.1±0.1
<100%	9.8
100%-<200%	17.4
≥200%	65.6
Unknown	7.2
<b>Urban-Rural Residence:</b>	
Metropolitan	45.1
Other	54.9
<b>Smoking status:</b>	
Current smoker	33.2
Ex-smoker	31.4
Never smoker	35.4
	<b>Mean±SEM or %</b>
<b>Alcohol use – past 12 months:</b>	
Yes	70.8
No	21.7
Unknown	7.5
<b>Body Mass Index (kg/m<sup>2</sup>):</b>	
Mean±SEM	26.7 ± 0.4
<25	44.9
25-<30	36.7
≥30	18.3
<b>Waist-to-Hip Ratio:</b>	
≤0.9	29.4
>0.9	70.6
<b>Self-Rated Health:</b>	
Excellent	25.5
Very Good	29.9

**Continuation of Table 1.**

Good	30.5
Fair	11.3
Poor	2.7
<b>History of Major Chronic Conditions<sup>*</sup>:</b>	
Yes	28.4
No	71.6
<b>Physical Activity (Metabolic Equivalents):</b>	
Mean±SEM	139.3±8.2
0	8.4
>0-<100	41.5
100-<200	25.9
200-<300	11.3
≥300	12.8
<b>Vitamin D (ng/ml)</b>	
Median [IQR]	26.7 [20.2-34.3]
Sufficient (≥ 30)	50.3
Insufficient (20-<30)	33.1
Deficient (<20)	16.5
<b>Testosterone (ng/mL):</b>	
Median [IQR]	5.4±0.15.15 [3.97-6.56]
<b>Estradiol (pg/mL):</b>	
Median [IQR]	37.2±0.735.4 [29.5-43.7]
<b>Sex hormone-binding globulin (nmol/L):</b>	
Median [IQR]	37.9±0.836.1 [25.9-49.7]

\* Major chronic conditions include self-reported physician diagnosis of arthritis, asthma, chronic bronchitis, congestive heart failure, diabetes, emphysema, stroke, skin cancer and other cancer.

mortality across quintiles of testosterone, estradiol and SHBG, and according to vitamin D status. Log-rank tests suggested statistically significant crude differences ( $P<0.0001$ ) in survival according to quintiles of testosterone and SHBG, but not according to estradiol level or vitamin D status (**Figures 1A-1D**).

**Table 3** presents Cox regression models for circulating vitamin D ( $\log_e$ -transformed and categorical) and biomarkers of sex steroid hormones ( $\log_e$ -transformed) as predictors of all-cause mortality, while examining linearity and interaction effects. Vitamin D deficiency but not insufficiency was significantly related to all-cause mortality in age-adjusted but not in fully-adjusted models. By contrast,  $\log_e$ -transformed vitamin D concentration and biomarkers of sex steroid hormones did not exhibit a linear relationship to all-cause mortality rate in either age-adjusted or fully-adjusted models. By including quadratic terms, we observed an inverse non-linear relationship between all-cause mortality rate and levels of testosterone, estradiol and vitamin D, in fully-adjusted models. Furthermore, there were no significant interaction effects between vitamin

**Table 2. Circulating Biomarkers of Sex Steroid Hormones Concentrations among Vitamin D Sufficient, Insufficient and Deficient Adult Men in the Study Sample (n=1472)-Third National Health and Nutrition Examination Survey.**

Mean±SD	Vitamin D status			P-value <sup>*</sup> 2 vs. 1 3 vs. 1 2 vs. 3
	Group 1 Sufficient	Group 2 Insufficient	Group 3 Deficient	
Testosterone (ng/mL)	5.5±2.1	5.2±1.9	5.1±2.0	0.1 <sup>ns</sup> 0.03 <sup>ns</sup> 0.4 <sup>ns</sup>
Estradiol (pg/mL)	36.8±13.3	36.9±11.0	38.9±13.4	0.6 <sup>ns</sup> 0.006 <sup>sign</sup> 0.02 <sup>ns</sup>
Sex hormone- binding globulin (nmol/L)	42.9±21.6	38.1±17.9	39.2±20.3	<0.0001 <sup>sign</sup> 0.003 <sup>sign</sup>

\* P values are determined based on one-way ANOVA tests for comparing log<sub>e</sub>-transformed testosterone, estradiol, sex hormone-binding globulin concentrations across vitamin D status groups.

D and sex steroid hormones in relation to all-cause mortality rate. We found no significant interaction effects between age group and the selected exposure variables; therefore, no stratified analyses were performed according to age group (data not shown).

## Discussion


In a population-based cohort study, we examined vitamin D and biomarkers of sex steroid hormones—separately and simultaneously—as predictors of all-cause mortality among adult men, 18 years and older, who participated in NHANES III. Significant differences in estradiol and SHBG concentrations were found across levels of vitamin D status. In age-adjusted but not fully-adjusted models, vitamin D deficiency was positively linked to all-cause mortality. Log<sub>e</sub>-transformed levels of vitamin D, testosterone and estradiol were non-linearly but inversely related to all-cause mortality, independently of baseline demographic, socioeconomic, lifestyle and clinical characteristics. There were no statistically significant interactions between vitamin D and biomarkers of sex steroid hormones in relation to all-cause mortality in age- or fully adjusted models.

Previously, Sempos and colleagues who analyzed the complete cohort of 15,099 NHANES III participants aged ≥20 years with 3,784 deaths reported over a 9-year follow-up period (1991-2000) found a reverse J-shaped association between serum vitamin D and all-cause mortality [35]. In another study of 1,114 NHANES III participants followed-up for a period of 18 years, differences in all-cause mortality were noticed between 90<sup>th</sup> and 10<sup>th</sup> percentiles of the sex hormone levels, including free and bioavailable testosterone [36]. Discrepancies between these studies and ours may be due to differences in exposure assessment and ability to detect

**Table 3. Cox proportional hazards models for Circulating Vitamin D and Log<sub>e</sub>-transformed Biomarkers of Sex Steroid Hormone Concentrations as predictors of Age-Adjusted and Fully-Adjusted All-Cause Mortality Rate among Adult Men in the Study Sample (n=1472)-Third National Health and Nutrition Examination Survey.**

Overall	Age-Adjusted		Fully-Adjusted	
	HR	95%CI	HR	95%CI
Testosterone	1.08	0.82-1.43	0.92	0.70-1.22
Estradiol	1.53	0.87-2.70	1.06	0.61-1.81
Sex hormone binding globulin:	1.42	0.79-2.54	1.23	0.70-2.17
Vitamin D-continuous	0.84	0.61-1.17	0.99	0.66-1.48
<b>Vitamin D-categorical:</b>				
Sufficient Vitamin D	Ref.	--	Ref.	--
Insufficient Vitamin D	0.97	0.69-1.35	0.92	0.65-1.29
Deficient Vitamin D	1.47	1.04-2.08	1.33	0.88-2.01
<b>Linearity</b>				
Testosterone	0.89	0.76-1.04	0.79	0.66-0.96
Testosterone <sup>2</sup>	1.22	1.08-1.40	1.19	1.03-1.38
Estradiol	0.08	0.01-0.54	0.05	0.004-0.76
Estradiol <sup>2</sup>	1.53	1.13-2.05	1.11	1.09-1.12
Sex hormone binding globulin	0.07	0.003-1.63	0.24	0.041-3.89
Sex hormone binding globulin <sup>2</sup>	1.50	0.98-2.31	1.25	0.84-1.86
Vitamin D	0.003	0.0002-0.07	0.01	0.0004-0.29
Vitamin D <sup>2</sup>	2.33	1.46-3.72	2.00	1.98-3.36
<b>Interactions</b>				
Testosterone	1.13	0.75-1.71	1.00	0.63-1.61
Insufficient Vitamin D	1.04	0.43-2.54	1.08	0.47-2.52
Deficient Vitamin D	1.67	0.49-2.54	1.79	0.58-5.54
Testosterone*Insufficient Vitamin D	0.96	0.51-1.79	0.90	0.48-1.68
Testosterone*Deficient Vitamin D	0.91	0.39-2.14	0.80	0.37-1.73
Estradiol	1.94	0.71-5.31	1.53	0.52-4.49
Insufficient Vitamin D	4.09	0.030-660.10	10.59	0.059-1876.57
Deficient Vitamin D	14.80	0.07-3342.88	14.12	0.04-4989.95
Estradiol*Insufficient Vitamin D	0.66	0.16-2.70	0.50	0.12-2.09
Estradiol*Deficient Vitamin D	0.52	0.12-2.33	0.51	0.10-2.56
SHBG	1.41	0.67-2.94	1.26	0.62-2.54
Insufficient Vitamin D	1.21	0.02-75.17	1.20	0.03-43.7
Deficient Vitamin D	0.62	0.017-23.04	0.99	0.05-20.9
SHBG*Insufficient Vitamin D	0.95	0.32-2.88	0.94	0.35-2.49
SHBG*Deficient Vitamin D	1.26	0.49-3.29	1.09	0.48-2.44

Fully-Adjusted Cox proportional hazards models included age, race/ethnicity, smoking status and physical activity.



small risk changes among groups. For instance, we defined testosterone as  $\log_e$ -transformed variables or in quintiles (taking the 3<sup>rd</sup> quintile as a referent) and our sample consisted of NHANES III participants with data available on vitamin D and biomarkers of sex steroid hormones [35,36].

To our knowledge, this epidemiological study is one of few to have simultaneously examined vitamin D, biomarkers of sex steroid hormones and all-cause mortality and the first to assess these associations using a nationally representative sample. Our study findings pertaining to vitamin D and biomarkers of sex steroid hormones as predictors of all-cause mortality are somewhat consistent with two previous studies [36,37]. In a large cohort of coronary angiography patients, Lerchbaum and colleagues observed that vitamin D and free T deficient men experienced the highest risk for all-cause mortality even after multivariable adjustment. Moreover, in men with vitamin D deficiency, low free T levels were associated with fatal events, whereas no association of free T with fatal events was found in men with vitamin D insufficiency or sufficiency [5]. In another study of 782 French men  $\geq 50$  years, Szulc and colleagues identified the lowest quartile of

vitamin D as predictor of mortality (HR=1.44, 95% CI: 1.03-2.03); estradiol level predicted mortality after the third year (HR=1.21 per 1 SD increase, 95% CI: 1.09-1.35), where by risk of death increased per quartiles of estradiol level and was higher in third and fourth quartiles compared with the lowest quartile (HR=1.80, 95% CI: 1.09-2.98 and HR=2.83, 95% CI: 1.71-4.67); mortality risk was not significantly associated with testosterone level [37]. Unlike the present study, no formal testing for interaction between vitamin D and biomarkers of sex steroid hormones was performed in these studies [36,37].

Whereas the link between vitamin D deficiency and all-cause mortality is well-established [38-41], the current epidemiological evidence linking endogenous total and free testosterone concentrations to mortality risk among men remains inconclusive. While total testosterone was mostly negatively related to mortality [13,14,16,20,42] with one study reporting a non-significant relationship [22], free testosterone was positively [22] or negatively [5] related to mortality and limited evidence suggests that SHBG may not be related [22] to mortality.

The finding that testosterone levels were negatively and

non-linearly related to all-cause mortality in fully-adjusted models is in line with the idea that as men age they experience a decline in testosterone [17,43], and is in line with another study [43]. In a case-cohort study of 495 elderly men (146 with ischemic arterial disease (IAD) and 349 controls), a J-shaped association was observed between total testosterone and IAD risk, whereby HR in the lowest and the highest quintiles relative to the second quintile were 2.23 (95% CI: 1.02; 4.88) and 3.61 (95% CI: 1.55; 8.45), respectively [43]. A similar J-shaped relationship was observed between IAD risk and free T, whereas SHBG was not significantly related to IAD risk [43].

The absence of a significant relationship between SHBG and all-cause mortality may be explained by the complex relationship among factors that determine SHBG level. Whereas the process of aging is accompanied by a rise in SHBG level, it is also accompanied by a rise in cardiovascular risk factors, such as obesity, insulin resistance, type 2 diabetes, hypertension, dyslipidemia and inflammation, which, in turn, are negatively correlated with SHBG level [17].

Our results should be interpreted with caution and in light of several limitations. First, the study design is observational and although cohort studies are considered as the gold standard in epidemiology, cause-and-effect relationships cannot be clearly established. Second, sex steroid hormones are known to vary on a diurnal basis, and the use of a single measurement for each of these biomarkers could potentially lead to non-differential misclassification bias. In addition, sex steroid hormones were measured by immunoassays and vitamin D was measured using DiaSorin (rather than mass spectrometry) which are now widely understood to be suboptimal for clinical research involving women, children or men with low serum testosterone [44,45] and especially for serum estradiol in men [46,47]. However, previous studies have indicated an association between testosterone levels and adverse events, irrespective of whether immunoassays or mass-spectrometry measurements were applied [5,14,15]. Third, the present study examined testosterone and SHBG levels but did not examine measures of free or bioavailable testosterone. Further analyses should be performed whereby 'free' testosterone is calculated using validated equations [48,49]. Fourth, sample size limitations may have precluded our ability to identify significant interactions between vitamin D and biomarkers of sex steroid hormones. Also, complete-subject analyses based on availability of data on key variables of interest may have resulted in selection bias. Fifth, the role of chance cannot be ruled out given the large number of statistical tests being conducted. Sixth, although numerous covariates were included in the multivariate models, residual confounding cannot be ruled out as an explanation for the observed associations. For instance, total caloric intake was measured using 24-hour recall which may be inadequate as an assessment of usual food consumption. Finally, our findings can only be generalized to adult men, and further research is needed to evaluate the role of sex steroid hormones in women as well as individuals

at different stages of life.

## Conclusion

Vitamin D, testosterone and estradiol, but not sex hormone binding globulin, may be inversely and non-linearly related to all-cause mortality among adult men, after adjustment for baseline characteristics. Future studies should attempt to elucidate the complex relationships of circulating vitamin D with sex steroid hormones and their impact on health-related outcomes among men. In particular, studies should assess the potentially mediating role of vitamin D in the relationship between circulating sex steroid hormones and age-adjusted mortality as well as the potentially mediating role of cardio-metabolic risk factors on the relationship between vitamin D and all-cause mortality.

## List of abbreviations

CI: Confidence Interval  
CYP2R1: 25-hydroxylase  
CYP27B1: 1- $\alpha$ -hydroxylase  
IAD: Ischemic arterial disease  
HR: Hazard Ratio  
NHANES: National Health and Nutrition Examination Survey  
PSU: Primary sampling unit  
SEM: Standard errors of the mean  
SHBG: Sex Hormone Binding Globulin

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

Authors' contributions	HAB	SME	HAJ	ABZ	MAB
Research concept and design	✓	✓	✓	✓	✓
Collection and/or assembly of data	✓	--	--	--	--
Data analysis and interpretation	✓	✓	✓	✓	✓
Writing the article	✓	✓	✓	✓	✓
Critical revision of the article	✓	✓	✓	✓	✓
Final approval of article	✓	✓	✓	✓	✓
Statistical analysis	✓	--	--	--	✓

## Acknowledgement and funding

This work was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging (NIA/NIH/IRP).

## Publication history

EIC: Masayoshi Yamaguchi, Emory University School of Medicine, USA.

Received: 02-Nov-2015 Final Revised: 13-Dec-2015

Accepted: 19-Dec-2015 Published: 28-Dec-2015

## References

1. Jones G, Strugnell SA and DeLuca HF. **Current understanding of the molecular actions of vitamin D.** *Physiol Rev.* 1998; **78**:1193-231. | [Article](#) | [PubMed](#)
2. Lerchbaum E and Obermayer-Pietsch B. **Vitamin D and fertility: a systematic review.** *Eur J Endocrinol.* 2012; **166**:765-78. | [Article](#) | [PubMed](#)
3. Brincat M, Gambin J and Calleja-Agius J. **The role of vitamin D in osteoporosis.** *Maturitas.* 2015; **80**:329-32. | [Article](#) | [PubMed](#)
4. Holick MF. **The role of vitamin D for bone health and fracture**

- prevention. *Curr Osteoporos Rep.* 2006; **4**:96-102. | [Article](#) | [PubMed](#)
5. Lerchbaum E, Pilz S, Boehm BO, Grammer TB, Obermayer-Pietsch B and Marz W. **Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography.** *Clin Endocrinol (Oxf).* 2012; **77**:475-83. | [Article](#) | [PubMed](#)
6. Pilz S, Dobnig H, Winkhofer-Roob B, Riedmuller G, Fischer JE, Seelhorst U, Wellnitz B, Boehm BO and Marz W. **Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography.** *Cancer Epidemiol Biomarkers Prev.* 2008; **17**:1228-33. | [Article](#) | [PubMed](#)
7. Holick M.F. **Vitamin D deficiency.** *N Engl J Med.* 2007; **357**:266-81.
8. Grundmann M and von Versen-Hoyneck F. **Vitamin D - roles in women's reproductive health?** *Reprod Biol Endocrinol.* 2011; **9**:146. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
9. Alpert PT and Shaikh U. **The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems.** *Biol Res Nurs.* 2007; **9**:117-29. | [Article](#) | [PubMed](#)
10. Blomberg Jensen M. **Vitamin D and male reproduction.** *Nat Rev Endocrinol.* 2014; **10**:175-86. | [Article](#) | [PubMed](#)
11. Ferlin A, Selice R, Carraro U and Foresta C. **Testicular function and bone metabolism—beyond testosterone.** *Nat Rev Endocrinol.* 2013; **9**:548-54. | [Article](#) | [PubMed](#)
12. Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK, Vandenput L, Borjesson AE and Ohlsson C. **Sex steroid actions in male bone.** *Endocr Rev.* 2014; **35**:906-60. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
13. Ohlsson C, Wallaschowski H, Lunetta KL, Stolk L, Perry JR, Koster A, Petersen AK, Eriksson J, Lehtimäki T, Huhtaniemi IT and Hammond GL et al. **Genetic determinants of serum testosterone concentrations in men.** *PLoS Genet.* 2011; **7**:e1002313. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
14. Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Barany P, Heimbürger O and Stenvinkel P. **Low serum testosterone increases mortality risk among male dialysis patients.** *J Am Soc Nephrol.* 2009; **20**:613-20. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
15. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT and Wittert GA. **Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis.** *J Clin Endocrinol Metab.* 2011; **96**:3007-19. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
16. Khaw KT, Dowsett M, Folkard E, Bingham S, Wareham N, Luben R, Welch A and Day N. **Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study.** *Circulation.* 2007; **116**:2694-701. | [Article](#) | [PubMed](#)
17. Yeap BB. **Testosterone and ill-health in aging men.** *Nat Clin Pract Endocrinol Metab.* 2009; **5**:113-21. | [Article](#) | [PubMed](#)
18. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D'Agostino R and Vasan RS. **Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts.** *J Clin Endocrinol Metab.* 2011; **96**:2430-9. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
19. Svartberg J, Schirmer H, Wilsgaard T, Mathiesen EB, Njolstad I, Lochen ML and Jorde R. **Single-nucleotide polymorphism, rs1799941 in the Sex Hormone-Binding Globulin (SHBG) gene, related to both serum testosterone and SHBG levels and the risk of myocardial infarction, type 2 diabetes, cancer and mortality in men: the Tromsø Study.** *Andrology.* 2014; **2**:212-8. | [Article](#) | [PubMed](#)
20. Haring R, Teumer A, Volker U, Dorr M, Nauck M, Biffar R, Volzke H, Baumeister SE and Wallaschowski H. **Mendelian randomization suggests non-causal associations of testosterone with cardiometabolic risk factors and mortality.** *Andrology.* 2013; **1**:17-23. | [Article](#) | [PubMed](#)
21. Atlantis E, Martin SA, Haren MT, O'Loughlin PD, Taylor AW, Anand-Ivell R, Ivell R and Wittert GA. **Demographic, physical and lifestyle factors associated with androgen status: the Florey Adelaide Male Ageing Study (FAMAS).** *Clin Endocrinol (Oxf).* 2009; **71**:261-72. | [Article](#) | [PubMed](#)
22. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ and McKinlay JB. **Sex steroids and all-cause and cause-specific mortality in men.** *Arch Intern Med.* 2007; **167**:1252-60. | [Article](#) | [PubMed](#)
23. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A and Choong K et al. **Adverse events associated with testosterone administration.** *N Engl J Med.* 2010; **363**:109-22. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
24. Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS and Ho PM. **Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.** *JAMA.* 2013; **310**:1829-36. | [Article](#) | [PubMed](#)
25. Saad F. **The role of testosterone in type 2 diabetes and metabolic syndrome in men.** *Arq Bras Endocrinol Metabol.* 2009; **53**:901-7. | [Article](#) | [PubMed](#)
26. Papatheodorou SI, Rohrmann S, Lopez DS, Bradwin G, Joshu CE, Kanarek N, Nelson WG, Rifai N, Platz EA and Tsilidis KK. **Association between endogenous sex steroid hormones and insulin-like growth factor proteins in US men.** *Cancer Causes Control.* 2014; **25**:353-63. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
27. Gershman B, Shui IM, Stampfer M, Platz EA, Gann PH, Sesso HL, DuPre N, Giovannucci E and Mucci LA. **Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer.** *Eur Urol.* 2014; **65**:683-9. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
28. NCHS. **Plan and operation of the third National Health and Nutrition Examination Survey.** *Vital Health Stat.* 1994.
29. NCHS. **Office of Analysis and Epidemiology, Public-use Third National Health and Nutrition Examination Survey Linked Mortality File.** 2010.
30. Phinney KW. **Development of a standard reference material for vitamin D in serum.** *Am J Clin Nutr.* 2008; **88**:511S-512S. | [Article](#) | [PubMed](#)
31. Yetley EA, Pfeiffer CM, Schleicher RL, Phinney KW, Lacher DA, Christakos S, Eckfeldt JH, Fleet JC, Howard G, Hoofnagle AN, Hui SL, Lensmeyer GL, Massaro J, Peacock M, Rosner B, Wiebe D, Bailey RL, Coates PM, Looker AC, Sempos C, Johnson CL and Picciano MF. **NHANES monitoring of serum 25-hydroxyvitamin D: a roundtable summary.** *J Nutr.* 2010; **140**:2030S-45S. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
32. Wheeler MJ. **The determination of bio-available testosterone.** *Ann Clin Biochem.* 1995; **32 ( Pt 4)**:345-57. | [PubMed](#)
33. Thienpont LM, Verhaeghe PG, Van Brussel KA and De Leenheer AP. **Estradiol-17 beta quantified in serum by isotope dilution-gas chromatography-mass spectrometry: reversed-phase C18 high-performance liquid chromatography compared with immuno-affinity chromatography for sample pretreatment.** *Clin Chem.* 1988; **34**:2066-9. | [Article](#) | [PubMed](#)
34. Pugeat M, Crave JC, Tourniaire J and Forest MG. **Clinical utility of sex hormone-binding globulin measurement.** *Horm Res.* 1996; **45**:148-55. | [Article](#) | [PubMed](#)
35. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, Yetley EA, Looker AC, Schleicher RL, Cao G, Burt V, Kramer H, Bailey RL, Dwyer JT, Zhang X, Gahche J, Coates PM and Picciano MF. **Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES.** *J Clin Endocrinol Metab.* 2013; **98**:3001-9. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
36. Menke A, Guallar E, Rohrmann S, Nelson WG, Rifai N, Kanarek N, Feinleib M, Michos ED, Dobs A and Platz EA. **Sex steroid hormone concentrations and risk of death in US men.** *Am J Epidemiol.* 2010; **171**:583-92. | [Article](#) | [PubMed](#)
37. Szulc P, Claustrat B and Delmas PD. **Serum concentrations of 17beta-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men—the MINOS study.** *Clin Endocrinol (Oxf).* 2009; **71**:594-602. | [Article](#) | [PubMed](#)
38. Keum N and Giovannucci E. **Vitamin D supplements and cancer incidence and mortality: a meta-analysis.** *Br J Cancer.* 2014; **111**:976-80. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)

39. Schottker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot L, Streppel M, Gardiner J, Ordóñez-Mena JM, Perna L and Wilsgaard T et al. **Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States.** *BMJ*. 2014; **348**:g3656. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
40. Shui I and Giovannucci E. **Vitamin D status and cancer incidence and mortality.** *Adv Exp Med Biol*. 2014; **810**:33-51. | [PubMed](#)
41. Zittermann A and Prokop S. **The role of vitamin D for cardiovascular disease and overall mortality.** *Adv Exp Med Biol*. 2014; **810**:106-19. | [Article](#) | [PubMed](#)
42. Ponikowska B, Jankowska EA, Maj J, Wegrzynowska-Teodorczyk K, Biel B, Reczuch K, Borodulin-Nadzieja L, Banasiak W and Ponikowski P. **Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease.** *Int J Cardiol*. 2010; **143**:343-8. | [Article](#) | [PubMed](#)
43. Soisson V, Brailly-Tabard S, Helmer C, Rouaud O, Ancelin ML, Zerhouni C, Guiochon-Mantel A and Scarabin PY. **A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study.** *Maturitas*. 2013; **75**:282-8. | [Article](#) | [PubMed](#)
44. Rosner W, Auchus RJ, Azziz R, Sluss PM and Raff H. **Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.** *J Clin Endocrinol Metab*. 2007; **92**:405-13. | [PubMed](#)
45. Handelsman DJ and Wartofsky L. **Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism.** *J Clin Endocrinol Metab*. 2013; **98**:3971-3. | [Article](#) | [PubMed](#)
46. Rosner W, Hankinson SE, Sluss PM, Vesper HW and Wierman ME. **Challenges to the measurement of estradiol: an endocrine society position statement.** *J Clin Endocrinol Metab*. 2013; **98**:1376-87. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
47. Handelsman DJ, Newman JD, Jimenez M, McLachlan R, Sartorius G and Jones GR. **Performance of direct estradiol immunoassays with human male serum samples.** *Clin Chem*. 2014; **60**:510-7. | [Article](#) | [PubMed](#)
48. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C and Handelsman DJ. **Accuracy of calculated free testosterone formulae in men.** *Clin Endocrinol (Oxf)*. 2010; **73**:382-8. | [Article](#) | [PubMed](#)
49. Sartorius G, Ly LP, Sikaris K, McLachlan R and Handelsman DJ. **Predictive accuracy and sources of variability in calculated free testosterone estimates.** *Ann Clin Biochem*. 2009; **46**:137-43. | [Article](#) | [PubMed](#)

**Citation:**

Beydoun HA, Eid SM, Jeng HA, Zonderman AB and Beydoun MA. **Vitamin D and biomarkers of sex steroid hormones are non-linearly and inversely related to all-cause mortality: results from NHANES III.** *Horm Stud*. 2015; **3**:1.  
<http://dx.doi.org/10.7243/2052-8000-3-1>